

Congress of the United States
House of Representatives

COMMITTEE ON OVERSIGHT AND REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5051
MINORITY (202) 225-5074
<http://oversight.house.gov>

June 21, 2019

Mr. Richard A. Gonzalez
Chairman and Chief Executive Officer
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064

Dear Mr. Gonzalez:


On January 14, 2019, the Committee sent a letter requesting several categories of documents and information related to your company's pricing practices for Humira and Imbruvica. This letter was sent to you as part of a Committee investigation into the actions of major pharmaceutical companies in raising prescription drug prices in the United States. The Committee is investigating why drug companies are raising their prices so dramatically, how they are using the proceeds, and what steps can be taken to reduce prescription drug prices.

It has now been almost six months since the Committee sent you this request. Although your company has provided the Committee with some information, it has not yet fully complied with the Committee's request. Although Committee staff have been in discussions with your company, you have not yet provided a date by which your productions will be complete.

I am writing today to explain that the Committee expects your company to produce all of the documents and information needed to carry out this investigation by July 18, 2019. Should you fail to do so, the Committee will have no choice but to consider alternative measures to obtain compliance. Committee staff will be following up with you directly in the coming week to discuss this schedule and our specific requests.

Thank you for your attention to this matter.

Sincerely,



Elijah E. Cummings
Chairman

cc: The Honorable Jim Jordan, Ranking Member